Equities

Natural Alternatives International Inc

Natural Alternatives International Inc

Actions
  • Price (EUR)3.96
  • Today's Change-0.22 / -5.26%
  • Shares traded500.00
  • 1 Year change-29.91%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024 20:50 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Natural Alternatives International, Inc. is a formulator, manufacturer and marketer of nutritional supplements. Its primary business activity is to provide private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbs, and other nutritional supplements, as well as other health care products, to consumers both within and outside the United States. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer ecommerce channels, and retail stores. It manufactures products in a variety of forms, including capsules, tablets, chewable wafers, and powders to accommodate a variety of its customer’s preferences. It also seeks to commercialize its patent and trademarks through the direct distribution and sale of CarnoSyn, SR CarnoSyn, TriBsyn, new contract manufacturing opportunities, and various license, royalty, and similar arrangements.

  • Revenue in USD (TTM)113.80m
  • Net income in USD-7.22m
  • Incorporated1989
  • Employees296.00
  • Location
    Natural Alternatives International Inc1535 Faraday AvenueCARLSBAD 92008United StatesUSA
  • Phone+1 (760) 736-7700
  • Fax+1 (760) 744-9589
  • Websitehttps://www.nai-online.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.